Developing Therapeutics That Teach the Body to Heal Itself
NEWS RELEASES
Search all of our news releases here.
American Gene Technologies® Advances Closer to Demonstrating a Potential Cure for HIV
HIV cure clinical trial data shows safety and efficacy of AGT™ gene therapy treatment, the company will begin withdrawing participants from antiretrovirals in Q2 to test potential functional cure American Gene Technologies (AGT), a clinical-stage biotechnology company working to cure HIV, announced that the independent… [Read More]
American Gene Technologies® HIV Clinical Trial Shows Blood Markers of Efficacy in Two More Patients
Data from a Total of Five Patients Demonstrates Critical Markers of the Company’s HIV Cure Gene & Cell Therapy American Gene Technologies, a clinical-stage biotechnology company working to cure HIV, announced that it has reached another important milestone for its HIV cure program. Five participants were… [Read More]
American Gene Technologies® Appoints Dr. Drew Palin as Business and Strategy Advisor to the CEO
Dr. Palin’s expertise in the intersection of business and technology strengthens AGT™ capability to bring patient solutions to the market. American Gene Technologies (AGT) announces the appointment of Dr. Drew Palin as business and strategy advisor to Jeff Galvin, CEO. “I am excited to have… [Read More]
American Gene Technologies® HIV Clinical Trial Demonstrates Blood Markers of Efficacy
Data from the First Three Patients Shows Critical Markers of the HIV Cure Cell Therapy: Engraftment, Persistence, and Function of Infused Cells American Gene Technologies (AGT™), a clinical-stage biotechnology company working to cure HIV, announced that it has reached two important milestones for its HIV cure… [Read More]
American Gene Technologies Passes Major Milestone in Potential HIV Cure Clinical Trial with Third Patient Showing No Serious Adverse Effects (SAEs)
American Gene Technologies (AGT), a clinical-stage biotechnology company, announced that the independent Data Safety and Monitoring Board (DSMB) overseeing the trial of AGT’s HIV gene therapy found no serious adverse events (SAEs) from the treatment for the third patient and voted unanimously to allow AGT’s HIV… [Read More]
American Gene Technologies Appoints Dr. Marcus A. Conant as Special Advisor to the CEO
Dr. Conant, one of the first HIV/AIDS treatment pioneers, strengthens AGT’s capacity to progress toward a functional cure October 01, 2021 13:25 ET | Source: American Gene Technologies American Gene Technologies (AGT) announces the appointment of Dr. Marcus A. Conant, a leading dermatologist in the U.S. and… [Read More]
American Gene Technologies HIV Cure Clinical Trial Shows Additional Progress with No Serious Adverse Events (SAEs)
American Gene Technologies (AGT), a clinical-stage biotechnology company, announced that the independent Data Safety and Monitoring Board (DSMB) in charge of the trial safety found no serious adverse events (SAEs) from the treatment for the second patient and voted unanimously to allow AGT’s HIV cure program to… [Read More]
American Gene Technologies Appoints Dr. Robert R. Redfield as Special Advisor to the CEO
ROCKVILLE, MD. (PRWEB) SEPTEMBER 15, 2021 Dr. Redfield’s expertise in virology strengthens AGT’s capacity to develop innovative HIV treatments. American Gene Technologies (AGT) announces the appointment of Dr. Robert R. Redfield, former director of the Centers for Disease Control and Prevention (CDC) and co-founder of… [Read More]
HIV Cure Program Releases Initial Clinical Trial Data
ROCKVILLE, MD, July 15, 2021 /Globe Newswire/ — American Gene Technologies (AGT) announced today that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure program without modification, after safety analysis of the participant’s data revealed no adverse effects from the… [Read More]
AGT Announces Progress with HIV Cure Program, Phase 1 Clinical Trial
ROCKVILLE, MD, May 27, 2021 /PR Newswire/ — American Gene Technologies (AGT), a clinical-stage biotechnology company, announced treatment of the first participant in its Phase I clinical trial to evaluate safety of the cell and gene therapy product AGT103-T. Designated as the RePAIR trial (Restore… [Read More]
Subscribe to News Releases and News Updates
Subscribe to our news release and published article updates to be notified when we release new content!
